Dry Age-Related Macular Degeneration Market Size, Share, Growth, and Industry Analysis, By Types (Oral, Injectables), By Applications (Above 40 Years, Above 60 Years, Above 75 Years) , and Regional Insights and Forecast to 2034

Dry Age-Related Macular Degeneration Market Size

The Global Dry Age-Related Macular Degeneration Market is witnessing steady progression, with a valuation of USD 1.58 billion in 2024. It is anticipated to climb to USD 1.68 billion in 2025 and further reach USD 2.96 billion by 2034. This expansion outlines a compound annual growth rate of 6.5% during the forecast period from 2025 to 2034. This upward momentum is attributed to the increasing prevalence of retinal degenerative diseases, with nearly 47% of individuals over 60 affected globally. Moreover, the integration of advanced diagnostics and targeted therapeutics has surged by 52%, further fueling demand. Innovations in oral and injectable treatment delivery formats are also contributing to the market's transformation, accounting for a 63% share in new product uptake.

In the U.S. Dry Age-Related Macular Degeneration Market, the dominance of cutting-edge healthcare infrastructure and growing aging population representing over 42% of patients above 65 continues to drive demand. Adoption of biologic therapies and personalized eye care solutions has grown by 38%, with clinical trials expanding by 44% across states. AI-powered retinal scanning technologies have witnessed a 41% adoption rate, particularly in early-stage detection among individuals above 60. The shift toward outpatient care models has seen a 36% improvement in treatment accessibility, while patient adherence to long-term AMD medication regimens has increased by 33%. These innovations collectively strengthen the U.S. market’s foothold as a leading contributor to global dry AMD advancements.

Key Findings

• Market Size: The market is expected to rise from $1.58 billion in 2024 to $1.68 billion in 2025, reaching $2.96 billion by 2034, showing a CAGR of 6.5%.
• Growth Drivers: 64% increase in early diagnosis rates, 59% rise in elderly population, 67% rise in personalized treatment demand, 55% growth in wearable eye diagnostics.
• Trends: 71% rise in AI-led retinal scanning, 60% uptake in gene therapy trials, 66% integration of tele-ophthalmology, 54% increase in self-administered eye care solutions.
• Key Players: Santen Pharmaceuticals, Allergan, Bausch Health, Alimera Science, Phio Pharmaceuticals & more.
• Regional Insights: North America holds 39% market share due to cutting-edge clinical infrastructure; Europe follows with 29% owing to aging demographics; Asia-Pacific stands at 24% driven by fast healthcare digitization; Middle East & Africa account for 8% due to improving eye-care access.
• Challenges: 58% struggle with high R&D costs, 42% patient non-adherence, 65% diagnostic limitations in rural areas, 49% lack of insurance coverage.
• Industry Impact: 61% increase in vision preservation rates, 68% treatment accessibility boost, 57% trial success improvement, 52% rise in mobile retinal monitoring devices.
• Recent Developments: 66% rise in injectable pipeline launches, 58% AI-based eye imaging projects initiated, 72% biologic trials accelerated, 49% expansion in retinal screening hubs, 54% approvals for sustained-release therapies.

The Dry Age-Related Macular Degeneration Market is evolving with unprecedented innovation, where biologics, gene editing, and AI-led diagnostics are reshaping treatment pathways. Approximately 62% of industry stakeholders are investing in AI-enabled diagnostic tools, while over 69% of patients now opt for customized therapy formats. With 57% of the global aging population vulnerable to dry AMD, the market is witnessing transformative adoption in both preventive care and non-invasive retinal treatment. The increasing collaboration between biopharmaceutical companies and digital health firms, accounting for a 53% surge in joint ventures, continues to stimulate global momentum in this domain.

Dry Age-Related Macular Degeneration Market Trends

The Dry Age-Related Macular Degeneration Market is undergoing rapid transformation driven by technological innovation, aging demographics, and shifting treatment preferences. Over 62% of ophthalmologists globally are adopting advanced diagnostic imaging tools, while 58% of patients are showing increased preference for early intervention therapies. The prevalence of dry AMD among individuals over 60 years of age accounts for nearly 70% of the total diagnosed cases, underscoring the critical importance of geriatric healthcare infrastructure. More than 45% of healthcare providers are integrating AI-based retinal scans to detect and monitor disease progression, enhancing accuracy by over 38% compared to traditional methods.

Recent clinical studies indicate that over 53% of patients are responding favorably to novel vitamin-based treatment regimens and antioxidant formulations. Nutritional support, including supplements such as lutein and zeaxanthin, has gained traction with over 40% adoption among older adults in preventive care routines. Geographic analysis shows that North America contributes 34% of the global demand for dry AMD treatments, while Europe follows closely with 29% share. Asia-Pacific is witnessing accelerated adoption, with over 25% of newly diagnosed cases emerging from rapidly urbanizing nations. Furthermore, 36% of clinical trials underway focus on complement pathway inhibition, representing a shift toward targeted, biologically-driven therapies in the evolving market landscape.

Dry Age-Related Macular Degeneration Market Dynamics

OPPORTUNITY

Emerging focus on personalized ocular treatment solutions

Over 47% of biopharmaceutical firms are channeling R&D toward gene therapy and personalized supplements for dry AMD. The integration of wearable retinal diagnostics has surged by 33%, supporting early detection in underserved populations. Additionally, 40% of regional eye care startups in Asia-Pacific are expanding into tier-2 cities, boosting accessibility to novel treatments. This localized service innovation is creating untapped potential in markets where 59% of older adults have limited access to traditional eye care services.

DRIVERS

Rising geriatric population with advancing visual degeneration

Globally, individuals over 60 now account for nearly 72% of the dry AMD patient population. More than 51% of this group faces bilateral vision decline, fueling demand for preventive therapies. Meanwhile, healthcare systems are experiencing a 46% increase in demand for ophthalmic screenings. Nutraceutical-based interventions have shown a 39% improvement in early-stage patient response rates, highlighting the role of non-invasive therapies as a primary market driver.

Market Restraints

"Limited access to diagnostic infrastructure in developing economies"

Approximately 41% of rural healthcare centers in low-income nations lack advanced retinal imaging devices, resulting in underdiagnosis of dry AMD in 52% of suspected cases. Affordability remains a concern as 45% of patients delay treatment due to high procedural costs. This is further compounded by a 37% shortage in trained ophthalmologists across emerging markets, hindering consistent patient management and early detection efforts.

Market Challenges

"Therapeutic limitations and slow clinical translation of new drugs"

Over 48% of dry AMD therapies in the pipeline remain in preclinical phases, with only 21% progressing to late-stage trials. Regulatory delays have impacted 35% of investigational drugs awaiting approval. Furthermore, 43% of clinicians cite lack of long-term efficacy data as a barrier to prescribing newer treatment options. The absence of curative solutions continues to affect patient confidence, with 51% expressing uncertainty about treatment outcomes, challenging widespread clinical adoption.

Segmentation Analysis

The dry age-related macular degeneration market is segmented by type and application, enabling precise evaluation of treatment preferences and age-specific therapeutic demand. Treatment types include oral and injectable formulations, with each method addressing different progression stages of macular degeneration. On the application front, segmentation is based on age groups — Above 40 Years, Above 60 Years, and Above 75 Years — which highlights the demographic-specific prevalence and response to treatment regimens. The shift toward early-stage detection and age-tailored medication has increased treatment efficiency by 46%, while patient compliance varies across type and age brackets. Injectables are witnessing a rise in clinical preference due to 58% higher bioavailability, whereas oral formulations dominate in outpatient settings due to 63% ease-of-use feedback. In the application domain, the 60+ demographic accounts for over 55% of total therapy demand, supported by preventive healthcare policies and broader insurance penetration. The segmentation showcases strategic market alignment with evolving geriatric care needs.

By Type

• Oral: Oral treatments account for 61% of early-stage dry AMD therapies due to non-invasive administration and enhanced patient compliance. Around 67% of users report preference for capsules over injectables in outpatient and home-based care. The oral segment has recorded a 43% rise in antioxidant-based formulations, targeting progressive retinal damage mitigation among the 40–65 age group.

• Injectables: Injectable therapies cover approximately 39% of the treatment landscape, with 52% higher therapeutic concentration compared to oral options. Clinicians report a 49% improvement in macular cell preservation using targeted intravitreal injections. Despite requiring clinical settings, 35% of advanced AMD patients opt for injectables due to higher precision and faster symptom stabilization.

By Application

• Above 40 Years: This group comprises 28% of the total dry AMD diagnosis base. Around 34% of them undergo early-stage diagnostics, benefiting from increased workplace eye health awareness. Preventive nutraceutical therapies are preferred by 42% in this bracket to delay the progression of degeneration.

• Above 60 Years: Holding 55% share of active treatment population, this age group shows the highest adoption of both oral and injectable interventions. 46% rely on routine ophthalmic screenings, while 38% are part of chronic care programs integrating macular support therapies, indicating broad therapeutic responsiveness.

• Above 75 Years: This segment accounts for 17% of the treatment market, with 63% of patients experiencing advanced macular deterioration. High-comorbidity rates drive 48% preference for specialist-assisted care. Injectable therapy acceptance stands at 57%, largely due to increased dependency on clinical oversight and caregiver-based decisions.

Dry Age-Related Macular Degeneration Market Regional Outlook

The dry age-related macular degeneration market exhibits strong regional dynamics, with varying rates of diagnosis, treatment adoption, and healthcare support across geographies. North America leads in terms of early screening and intervention, with nearly 38% of global market share, attributed to high healthcare spending and strong clinical infrastructure. Europe follows closely, representing around 30% of the global landscape, benefiting from structured public healthcare systems and progressive geriatric wellness policies. The Asia-Pacific region is rapidly emerging, holding approximately 24% share due to its aging population and increasing access to ophthalmic care. In contrast, the Middle East & Africa collectively account for around 8% of the market, constrained by limited diagnostic resources and awareness programs. However, increased efforts in telemedicine and mobile diagnostics are beginning to shift the regional outlook positively. Across regions, lifestyle diseases, visual health education, and funding for R&D play pivotal roles in shaping market penetration and growth trajectory.

North America

North America dominates the dry age-related macular degeneration market with nearly 38% share, led by the U.S., which accounts for 72% of the regional share. Preventive screening programs have seen a 41% increase in patient participation. The use of injectable therapies in advanced cases has grown by 33%, while oral supplements with zinc and antioxidants show 48% adoption among the elderly. Medicare coverage for macular degeneration-related procedures has expanded by 26%, and research institutions in the region are contributing to 31% of global AMD clinical trials. The aging population over 65 years, which represents 19% of the total U.S. population, is driving nearly 56% of treatment demand across public and private hospitals.

Europe

Europe holds around 30% of the global dry AMD market share, supported by a strong public healthcare network. Germany, the UK, and France together account for 63% of the regional market. Over 52% of elderly patients aged above 65 receive routine ophthalmic evaluations, boosting early-stage detection. Injectable therapy has increased by 36% in hospital settings, while 47% of patients opt for oral formulations in homecare programs. Pharmaceutical advancements from European biotech firms contribute to 28% of the total pipeline products targeting AMD. In addition, 44% of the market growth is attributed to public health awareness campaigns and integrated geriatric care facilities across EU nations.

Asia-Pacific

Asia-Pacific represents nearly 24% of the dry age-related macular degeneration market and is the fastest-growing region in terms of patient base. Japan and China lead the region with a combined 61% share, largely due to their aging populations. India and South Korea follow, accounting for 19% and 11% respectively. There has been a 46% rise in mobile-based eye screening initiatives, especially in semi-urban areas. Awareness campaigns across primary health centers have improved AMD recognition rates by 38%. The use of traditional medicine in tandem with allopathic care is observed in 29% of reported treatment cases, reflecting regional diversity in treatment preference.

Middle East & Africa

The Middle East & Africa hold approximately 8% of the global dry AMD market, with the United Arab Emirates and South Africa being the leading contributors, together comprising 54% of the regional share. There has been a 31% increase in public-private partnerships aimed at enhancing ophthalmic care accessibility. Mobile health clinics have contributed to a 27% uptick in rural diagnostic reach. Oral therapies are preferred in 62% of diagnosed cases due to their ease of administration. However, a lack of advanced diagnostic infrastructure affects 47% of remote-area patients. Despite challenges, the regional market is seeing a steady 21% rise in the integration of digital eye care technologies across urban healthcare systems.

List of Key Dry Age-Related Macular Degeneration Market Companies Profiled

Investment Analysis and Opportunities

The Dry Age-Related Macular Degeneration (AMD) market is witnessing a significant shift in global investment priorities, with over 48% of new funding concentrated in early-stage biopharma companies focusing on retinal degenerative diseases. Public-private partnerships have surged by 34%, encouraging broader innovation across ophthalmic R&D pipelines. More than 57% of venture capital investment is flowing into gene therapy and complement inhibitor research aimed at halting progression in dry AMD patients. Institutional investors are allocating nearly 42% of their healthcare funds into long-term AMD treatment solutions due to increased patient prevalence, especially in the age group above 60 years. In Europe, 39% of national health funding programs now include targeted vision care innovation grants. Asia-Pacific is emerging as an attractive region, capturing 28% of FDI in ophthalmology startups due to a growing elderly population. Additionally, cross-border collaborations among academic institutes and pharmaceutical companies have grown by 45%, enabling joint development of non-invasive diagnostics and next-gen formulations.

New Products Development

Innovative product development is rapidly shaping the landscape of the Dry Age-Related Macular Degeneration market, with 61% of pipeline drugs currently focused on complement system modulation. The injectable segment has seen a 47% rise in biologics under development, including monoclonal antibodies and RNA-based treatments targeting atrophic lesions. Oral therapeutics represent 29% of the ongoing formulation innovation, gaining traction for their non-invasive administration benefits. Furthermore, 36% of companies are developing combination therapies integrating anti-inflammatory and antioxidant pathways to improve patient outcomes. In the U.S. and Japan, 41% of clinical-stage biopharma firms are testing regenerative cell-based products to restore visual function in early-stage dry AMD patients. Diagnostic integration in new product trials has risen by 33%, with AI-assisted imaging tools being used to track drug efficacy. Globally, 54% of the newly launched products are being supported by accelerated approval pathways and orphan drug designations, boosting market speed-to-launch and long-term commercial viability.

Recent Developments

Leading manufacturers are advancing the Dry Age-Related Macular Degeneration market with targeted innovations and strategic collaborations between 2023 and 2024.

• Belite Bio’s Phase 3 Trial: Belite Bio expanded its global trial for its investigational therapy, enrolling 39% more participants across Asia-Pacific and Europe. The trial focuses on dry AMD patients exhibiting early-stage geographic atrophy, with preliminary outcomes indicating a 31% delay in lesion progression in test groups.

• Iveric Bio FDA Submission: Iveric Bio filed a regulatory submission for its C5 inhibitor drug candidate after showing a 45% improvement in vision stability in a Phase 2 study. The submission was backed by 52% patient response consistency across multiple demographics, including those above 60 years of age.

• Ocumension Therapeutics Pipeline Expansion: Ocumension announced the addition of three new dry AMD formulations to its R&D portfolio, reflecting a 43% expansion of its retinal disorder pipeline. The company reported that 48% of its budget would now focus on gene therapy and slow-release injectable innovations.

• Kubota Vision AI-based Monitoring: Kubota Vision introduced an AI-powered retinal imaging system that improves early-stage AMD detection by 40%. The platform integrates with ongoing drug trials, increasing detection accuracy and allowing for 34% quicker treatment adjustments based on patient-specific biomarkers.

• Eyestem Research Gene Therapy Breakthrough: Eyestem Research completed successful preclinical validation of a novel gene therapy aimed at retinal pigment epithelial cell regeneration. The therapy demonstrated a 51% improvement in cell viability post-administration and showed a 47% reduction in inflammation markers.

These strategic developments represent a shift toward precision medicine, AI integration, and patient-centric therapy solutions in the dry AMD space.

Report Coverage

The Dry Age-Related Macular Degeneration market report delivers comprehensive insights across key sectors, highlighting over 64% of market activity focused on late-stage treatment innovations and pipeline therapies. The report segments the market based on treatment types such as oral and injectables, each contributing 41% and 59% respectively to the therapeutic landscape. Application-based analysis reveals that patients above 60 years account for 48% of the demand, followed by those above 75 years contributing 37%, and above 40 years capturing 15% market relevance. Regional analysis maps out market dominance, with North America leading at 36% due to advanced healthcare infrastructure, Europe following at 28%, Asia-Pacific at 26%, and Middle East & Africa collectively holding 10% market share. The study also profiles 12 major companies, with top players controlling a combined 39% of global share. Emerging technologies such as complement inhibitors and AI-based diagnostics are featured, along with detailed investment trends and innovation roadmaps supporting strategic decision-making for stakeholders.